Lantern Wealth Advisors LLC Purchases 11,352 Shares of Bristol-Myers Squibb (NYSE:BMY)

Lantern Wealth Advisors LLC raised its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 77.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 26,032 shares of the biopharmaceutical company's stock after acquiring an additional 11,352 shares during the quarter. Lantern Wealth Advisors LLC's holdings in Bristol-Myers Squibb were worth $1,472,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Fairway Wealth LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $28,000. Transce3nd LLC purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter worth $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $34,000. Tacita Capital Inc purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at $39,000. Finally, M Holdings Securities Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter worth $39,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. The Goldman Sachs Group reissued a "neutral" rating and set a $55.00 price target (down from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Piper Sandler started coverage on Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 price objective on the stock. UBS Group lowered their target price on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a research report on Friday, April 11th. Finally, William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $58.00.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock opened at $47.22 on Tuesday. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The company has a market capitalization of $96.10 billion, a price-to-earnings ratio of -10.68, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39. The company's 50 day simple moving average is $52.80 and its 200-day simple moving average is $55.94. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($4.40) earnings per share. As a group, equities research analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.25%. Bristol-Myers Squibb's dividend payout ratio is presently 92.88%.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction on Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.